Vabysmo is a bispecific antibody designed to inhibit vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2).
Foundayo, an oral GLP-1, now available and with new trial data; Filspari and Sdamlo gain approval; and the FDA invites ...
Social media posts about glucagon-like peptide-1 receptor agonists may identify patient concerns not captured in clinical trials, according to a study published ...
Federal health officials are considering Dr Erica Schwartz to lead the US Centers for Disease Control and Prevention (CDC), according to people familiar with th ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results